XNYS
MD
Market cap2.15bUSD
Oct 08, Last price
26.24USD
1D
1.59%
1Q
-0.11%
Jan 2017
-60.64%
Name
Pediatrix Medical Group Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
Key people
Executive Chairman of the Board, Chief Executive Officer · since 2025
Kasandra Rossi
Chief Financial Officer, Executive Vice President, Treasurer · since 2025
Mary Ann Moore
Executive Vice President, Chief Administrative Officer, General Counsel, Company Secretary · since 2024
James Swift
Director · since 2025
Laura Linynsky
Independent Director · since 2022
Independent Director · since 2020
Kurt Newman
Independent Director · since 2025
Michael Rucker
Independent Director · since 2019
Lead Independent Director · since 2023
John Starcher
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2023
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||